Array Biopharma suffered a serious knock back in early 2017 when its plan to commercialise its drug, binimetinib, were derailed by FDA scepticism of the strength of its data for the treatment of NRAS+ melanoma.
It has seemingly bounced back with data in the treatment of BRAF-mutant melanoma, when binimetinib combined with encorafenib resulted in an improvement to median overall survival by 33.6 months.
This compared extremely favourably to treatment with Roche’s vemurafenib when it was used as a monotherapy, which was only able to boost OS by 16.9 months.
